PetDx® Announces Publication of Landmark Clinical Validation Study for OncoK9®, Its Pioneering Multi-Cancer Early-Detection Liquid Biopsy Test for Dogs Using Next-Generation Sequencing; Study Published in PLOS ONE

On April 26, 2022, PetDx®--The Liquid Biopsy Company for Pets™ announced publication of a landmark study in PLOS ONE, a peer-reviewed open-access scientific journal from the Public Library of Science. The publication details the largest clinical validation study ever performed in veterinary cancer diagnostics and demonstrates that the performance of OncoK9®--The Liquid Biopsy Test for Dogs™ mirrors that of leading multi-cancer early detection (MCED) tests for humans. The CANcer Detection in Dogs (CANDiD) study, an international, multi-center clinical study, was designed to validate the performance of OncoK9–a novel MCED test for dogs using next-generation sequencing (NGS) of blood-derived DNA. "PetDx has made an unprecedented investment over the past few years to develop and validate a blood-based test for the detection and characterization of cancer in our canine companions. This landmark study, and our rich R&D pipeline in veterinary oncology, underscore our commitment to building PetDx into the world's leading veterinary cancer diagnostics company," said Daniel S. Grosu, MD, MBA, Founder and CEO of PetDx. The PLOS ONE article, published on April 26,2022, is titled “Clinical Validation of a Next-Generation Sequencing-Based Multi-Cancer Early Detection “Liquid Biopsy” Blood Test in Over 1,000 dogs Using an Independent Testing Set: The CANcer Detection in Dogs (CANDiD) Study.”